Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework. Zarka J, Childs DS, Muniz Rincon M, Tarhini A, et al. Oncologist 2026;31:oyag371.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zarka J, Childs DS, Muniz Rincon M, Tarhini A, et al. Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework. Oncologist 2026;31:oyag371.
PMID: 42768457